Head-to-head · WeighScore
Omada Health vs telos rx
The verdict
telos rx takes it — 85.4/100 to 55.6/100.
telos rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified, HIPAA telehealth with one of the deepest published catalogs on the board — compounded semaglutide and tirzepatide (oral and microdosed routes included) alongside PT-141, intranasal NAD+, and a long recovery/GH peptide bench — with compounded GLP-1 starting from $49/mo on an annual plan.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Omada Health | telos rx |
|---|---|---|
| WeighScore | 55.6/100 | 85.4/100 |
| Grade | C | B |
| Scorecard rank | #436 | #9 |
| Semaglutide | Not disclosed | From $49/mo (annual) |
| Tirzepatide | Not disclosed | $99/mo (annual) |
| Coverage | Coverage not published | Not publicly listed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Graded #9 · B
Strengths
- Deep published catalog — sema, tirz, PT-141, intranasal NAD+, recovery/GH peptides, GHK-Cu, Dihexa, HRT
- Needle-free and oral GLP-1 options, not injection-only
- LegitScript-certified and HIPAA, with US providers and pharmacies, HSA/FSA and free shipping
- Low GLP-1 entry — from $49/mo microdosed on an annual plan
Where it loses points
- Everything is compounded and not FDA-approved, including the peptides
- Pricing is opaque outside GLP-1 and the lowest rates require annual lock-in
- No named clinicians and thin third-party reviews
- Several research-grade peptides carry limited clinical evidence
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.